On the other hand, a recent study showed that the CRP flare-response, in which CRP rises rapidly at a very early phase of treatment and then falls shortly thereafter, is associated with better clinical outcomes in patients with RCC treated with nivolumab [78]. Here, CRP is linked to renal cell carcinoma.